## RESEARCH ARTICLE

**∂** OPEN ACCESS

# Quality of chronic kidney disease management in primary care: a retrospective study

Vincent A. Van Gelder<sup>a</sup>\*, Nynke D. Scherpbier-De Haan<sup>a</sup>\*, Wim J.C. De Grauw<sup>a</sup>, Gerald M.M. Vervoort<sup>b</sup>, Chris Van Weel<sup>a,d</sup>, Marion C.J. Biermans<sup>a</sup>, Jozé C.C. Braspenning<sup>c</sup> and Jack F.M. Wetzels<sup>b</sup>

<sup>a</sup>Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, the Netherlands; <sup>b</sup>Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands; <sup>c</sup>IQ Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, the Netherlands; <sup>d</sup>Australian Primary Health Care Research Institute, Australian National University, Canberra, Australia.

#### ABSTRACT

Background: Early detection and appropriate management of chronic kidney disease (CKD) in primary care are essential to reduce morbidity and mortality. Aim: To assess the quality of care (OoC) of CKD in primary healthcare in relation to patient and practice characteristics in order to tailor improvement strategies. Design and setting: Retrospective study using data between 2008 and 2011 from 47 general practices (207 469 patients of whom 162 562 were adults). Method: CKD management of patients under the care of their general practitioner (GP) was qualified using indicators derived from the Dutch interdisciplinary CKD guideline for primary care and nephrology and included (1) monitoring of renal function, albuminuria, blood pressure, and glucose, (2) monitoring of metabolic parameters, and alongside the guideline: (3) recognition of CKD. The outcome indicator was (4) achieving blood pressure targets. Multilevel logistic regression analysis was applied to identify associated patient and practice characteristics. Results: Kidney function or albuminuria data were available for 59 728 adult patients; 9288 patients had CKD, of whom 8794 were under GP care. Monitoring of disease progression was complete in 42% of CKD patients, monitoring of metabolic parameters in 2%, and blood pressure target was reached in 43.1%. GPs documented CKD in 31.4% of CKD patients. High QoC was strongly associated with diabetes, and to a lesser extent with hypertension and male sex. **Conclusion:** Room for improvement was found in all aspects of CKD management. As QoC was higher in patients who received structured diabetes care, future CKD care may profit from more structured primary care management, e.g. according to the chronic care model.

#### **KEY POINTS**

- Quality of care for chronic kidney disease patients in primary care can be improved.
- In comparison with guideline advice, adequate monitoring of disease progression was observed in 42%, of metabolic parameters in 2%, correct recognition of impaired renal function in 31%, and reaching blood pressure targets in 43% of chronic kidney disease patients.
- Quality of care was higher in patients with diabetes.
- Chronic kidney disease management may be improved by developing strategies similar to diabetes care.

# Introduction

General practitioners (GPs) play a key role in the complex care of patients with chronic kidney disease (CKD). The K/DOQI guidelines (USA) and the National Institute for Health and Clinical Excellence (NICE) CKD guideline (UK) provide GPs with recommendations on good CKD management, including monitoring of disease progression and strictly controlling cardiovascular risk factors.[1,2] The Dutch interdisciplinary CKD guideline for primary care and nephrology is similar to these guidelines, but incorporates age in its recommendations (Web appendix Table 1).[3]

Studies have shown that high standard CKD management attenuates and delays adverse outcomes such as progression to end-stage renal failure and cardiovascular events.[4,5] However, literature also notes deficiencies in the quality of care (QoC).[6,7] The high

#### **ARTICLE HISTORY**

Received 27 October 2014 Accepted 22 November 2015

#### **KEYWORDS**

Chronic kidney disease; electronic medical records; general practice; primary health care; quality of health care; the Netherlands



CONTACT Vincent van Gelder, MD MSc S Vincent.vanGelder@radboudumc.nl Department of Primary and Community Care, Postal Route 117, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, the Netherlands \*Both authors contributed equally to the manuscript

Supplemental data for this article can be accessed here.

<sup>© 2016</sup> The Author(s). Published by Taylor & Francis. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http:// creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prevalence of comorbidity challenges the GP to balance guideline advice to the patient's individual needs.[8]

Our study aimed to analyse QoC in routine general practice for all stages of CKD, in relation to patient and practice characteristics. We hypothesized that our study would reveal predictors of high QoC.

# Material and methods

# **Recruitment of participants**

This retrospective study used baseline patient data of general practices that participated in a cluster randomized controlled trial on the effect of web consultation between GP and nephrologist on in-person referrals: the CONTACT study (Consultation Of Nephrology by Telenephrology Allows optimal Chronic kidney disease Treatment in primary care, Netherlands Trial Registration code 2368). The CONTACT study recruited general practices during a CKD management course for GPs. Forty-seven non-academic general practices signed up for participation. Data between 2008 and 2011 were analysed from their registered populations' electronic medical records (EMRs) (n = 207 469). We included all patients aged 18 years or older who met the CKD  $eGFR < 60 ml/min/1.73 m^2$ or albuminuria. criteria: Patients under secondary renal care were excluded from analysis.

# **Classification of patients**

The interdisciplinary CKD guideline for primary care and nephrology provides guidance for the GP in selecting the best suited health care setting for patients with CKD, based on eGFR, albuminuria and age. These settings are: treatment in primary care, consultation with a nephrologist without referral, and referral to secondary care. The guideline provides specific monitoring criteria for each group. We applied this classification to our cohort, resulting in a primary care, a consultation, and a referral group (Table 1). For the primary care group this implied monitoring of disease progression, while the consultation and the referral groups additionally required monitoring of metabolic parameters (Web appendix Table 1). We used laboratory-reported MDRD calculated eGFR values and in congruence with the quideline we defined microalbuminuria as a urinary albumin to creatinine ratio (ACR) of 2.5-25mg/mmol in men and 3.5-35mg/mmol in women. Higher ratios reflected macroalbuminuria. If an ACR was unavailable, we used urine albumin concentration with cut-off values > 20–200mg/l for microalbuminuria and > 200 Table 1. Classification of adult patients with available renal function using the interdisciplinary CKD guideline for primary care and nephrology.

			Albuminuria	
	Not known	Normal	Microalbuminuria	Macroalbuminuria
Patients $\geq$ 65 ye	ears (n = 19 8	387)		
$eGFR \ge 60$	7.696	5.467	893	74
eGFR 45-60	2.085	1.632	411	52
eGFR 30-45	620	442	195	46
eGFR < 30	179	44	33	18
Patients < 65 ye	ears (n = 39 8	841)		
$eGFR \ge 60$	28.927	8.350	693	59
eGFR 45-60	869	620	70	16
eGFR 30-45	102	55	22	7
eGFR < 30	33	4	6	8

Classification of patients based on renal function, albuminuria and age. "Primary care group" n = 5714: treatment in primary care. "Consultation group" n = 2816: consultation with a nephrologist without referral. "Referral group" n = 758: referral to secondary care. eGFR in ml/min/ 1.73m<sup>2</sup>

mg/l for macroalbuminuria. Patient age was set on the latest eGFR date.

#### Process and outcome indicators

We derived indicators (Table 2) from the interdisciplinary CKD guideline for primary care and nephrology.[3] Included process indicators were: (1) monitoring of disease progression (assessment of eGFR or serum creatinine, albuminuria, glucose, and blood pressure); (2) monitoring of metabolic parameters (assessment of haemoglobin, calcium, phosphate, parathyroid hormone (PTH), serum albumin, and potassium), and alongside the guideline: (3) recognition of CKD in patients with an eGFR < 60ml/min/1.73m<sup>2</sup> (separate entity on the EMR episode list with International Classification of Primary Care (ICPC) code U99.1 for renal impairment). The outcome indicator was (4) achievement of blood pressure targets, for which the mean of the two latest measurements had to be <140/90mmHg. Additionally, we analysed blood pressures <130/80mmHg to allow comparison with existing literature.

# Patient and practice characteristics

We extracted patient demographic and clinical data concerning comorbidities and medication from the EMRs (Table 3). Patient age was categorized in ranges 18–45, 45–60, 60–75, and over 75 years. Comorbidities were defined by ICPC codes as a history of diabetes (T90), hypertension (K86,K87), and cardiovascular disease (K74-K77,K89,K90,K92).[9] We selected drug prescriptions issued during 2010 for medication shown in Table 3 using Anatomical Therapeutic Chemical (ATC) codes.[10]

Practice characteristics included type (solo, duo, or group practice), vocational training, location (urban or

Table 2. Performance on process and outcome indicators within 15 months prior to data extraction for patients under GP care.

sure targets	< 130/80 mmHg*	90 (12%)		84 (16%)	478 (16%)	652 (15.1%)			196 (22%)	149 (16%)	345 (19.2%)			18 (38%)	10 (26%)	1 (100%)	13 (10%)	42 (19.5%)		387 (19.2%)		1039 (16.4%)		
Blood pres	<140/90 mmHg*	265 (34%)		249 (47%)	1234 (41%)	1748 (40.5%)			427 (48%)	465 (51%)	892 (49.6%)			24 (50%)	23 (61%)	1 (100%)	35 (27%)	83 (38.6%)		975 (48.4%)		2723 (43.1%)		
	Recognition				1088 (26%)				721 (58%)	324 (21%)	1045 (37.6%)			47 (59%)	28 (44%)	3 (50%)	26 (38%)**	104 (47.9%)**		1149 (38.3%)**		2237 (31.4)**		
	i Complete	1							51 (4%)	19 (1%)	70 (2.5%)			1 (1%)	2 (3%)	0 (0%)	1 (1%)	4 (1.3%)		74 (2.4%)				
eters	n Potassium								872	816	1688	(60.7%)		59	39	m	117	218	(71.7%)	1906	(61.8%)			
abolic param	Serum Pth albumi								5 124	2 49	173	.8%) (6.2%)		13	80	2	12	35	.3%) (11.5%)	14 208	.7%) (6.7%)			
oring of met	hosphate								59 75	4 37	33 10	8.4%) (3		3 2	1 2	0	0 3	5 7	11.5%) (2	.68 1	8.7%) (3			
Monit	in Calcium F								194 1	96 7	290 2	(10.4%)		20	14 1	2	19 1	55 3	(18.1%) (	345 2	(11.2%) (			
	Haemoglobi								696	645	1341	(48.2%)		58	36	4	60	158	(52.0%)	1499	(48.6%)			
on	Complete	676 (76%)		455 (66%)	1529 (37%)	2660 (46.6%)			451 (37%)	447 (29%)	898 (32.3%)			16 (20%)	16 (25%)	(%0) 0	104 (67%)	136 (44.7%)		1034 (33.5%)		3694 (42.0%)		
e progressi	Blood pressure	776		532	3003	4311	(75.5%)		892	907	1799	(64.7%)		48	38	1	128	215	(70.7%)	2014	(65.3%)	6325	(71.9%)	
g of diseas	Fasting a glucose	795	l	565	2573	3933	(%6.89)		703	844	1547	(22.6%)		35	38	-	135	209	(68.8%)	1756	(26.9%)	5689	(64.7%)	
Monitorin	Albuminuri	763		555	1686	3004	(52.6%)		501	540	1041	(37.4%)		18	20	0	118	156	(51.3%)	1197	(38.8%)	4201	(47.8%)	
	Renal function	817		588	3403	4808	(84.2%)		1023	1131	2154	(77.5%)		67	49	с	137	256	(84.2%)	2410	(78.1%)	7218	(82.1%)	
	L	892		693	4125	5710			1235	1545	2780			79	63	9	156	304		3084		8794		
	Patient group	Primary care group: Age > 65 eGFR > 60	and microalbuminuria	Age < 65 eGFR ≥ 60 and microalbuminuria	Age $\ge$ 65 eGFR 45–60	Total primary care		Consultation group:	Age ≥ 65 eGFR 30 – 45	Age < 65 eGFR 45-60	Total consultation group		Referral group:	Age $\ge 65$ eGFR < 30	Age < 65 eGFR 30-45	Age < 65 eGFR < 30	Macroalbuminuria	Total Referral group		Total consultation and	referral group	Total		

riocess' and outcome inductions are derived from the interdisciplinary των gurdeme for primary care and neprirology, or ex-creatinine; albuminuria: albumin creatinine ratio or urine albumin. eGFR in ml/min/1.73m<sup>2</sup>. \*Percentages show the achieved blood pressure targets divided by the number of blood pressure measurements. \*\*Percentage calculated with patients with eGFR < 60 ml/min/1.73m<sup>2</sup> as denominator (n = 69 in macroalbuminuria group). Process

#### Table 3. Patient characteristics based on data from 2008 to 2011 for patients under GP care.

Overall (n = 8794)Primary care (n = 5710)Consultation (n = 2780)Referral (n = 304)Demographics (SD): Age in years714 (11.9)736 (10.2)66.7 (13.3)72.3 (14.0)Male sex40.0%42.7%33.6%47.0%Comorbidity: Diabetes52.9%56.0%24.5%52.6%Objecters52.9%57.8%53.5%52.0%Cardiovascular disease35.6%36.1%32.4%50.6%Laboratory (SD), n: Creatinine, µmol/l103.9(25.9) (n = 8792)95.6 (18.5) (n = 5709)117.4 (23.7) (n = 2779)136.7 (61.6) (n = 304]Fasting glucose, mmol/l6.5 (1.8) (n = 8794)55.4 (4.9) (n = 5710)47.7 (9.0) (n = 2780)43.0 (15.1) (n = 204]Fasting glucose, mmol/l6.5 (1.8) (n = 8794)55.4 (4.9) (n = 5710)47.7 (9.0) (n = 2780)43.0 (15.1) (n = 204]Phosphate, mmol/l6.5 (1.8) (n = 6938)6.6 (1.9) (n = 4689)6.2 (1.6) (n = 1980)7.0 (2.3) (n = 2271)Albumin, urine, mg/l7.5 (0.6) (n = 0.502)3.2 (0.96.4) (n = 3557)3.8 (4.4) (n = 771)3.8 (6.4) (n = 771)Albumin urine, mg/l7.5 (0.3.4 - 51.0) (n = 2928)3.2 (0.96.4) (n = 35577)0.9 (0.8-8.3) (n = 721)210.6 (84.3 - 480.2) (n = 158)Albumin/creatinine ratio7.5 (1.9.7) (n = 7290)14.8 (17.4) (n = 4889)7.9.1 (9.9) (n = 2147)7.86 (11.3) (n = 255)Physical examination (SD), n7.88 (9.7) (n = 7291)14.8 (17.4) (n = 4889)7.9.1 (9.9) (n = 2147)7.86 (11.3) (n = 255)Medication prescribed in 2010:7.86 (9.5) (n = 4889)7.9.1 (9.9) (n = 2	Patient characteristic		Gro	oups	
Demographics (SD):         71.4 (11.9)         73.6 (10.2)         66.7 (13.3)         72.3 (14.0)           Male sex         40.0%         42.7%         33.6%         47.0%           Comorbidity:		Overall (n = 8794)	Primary care (n = 5710)	Consultation (n $=$ 2780)	Referral (n = 304)
Age in years71.4 (11.9)73.6 (10.2)66.7 (13.3)72.3 (14.0)Male sex40.0%42.7%33.6%47.0%Comorbidity:73.6 (10.2)36.0%24.5%52.6%Diabetes32.9%36.0%53.5%52.0%Gardiovascular disease35.6%36.1%32.4%53.6%Laboratory (SD), n:77.6 (10.2)103.9(25.9) [n = 8792]95.6 (18.5) [n = 5709]117.4 (23.7) [n = 2779]43.0 (15.1) [n = 304]eGFR, ml/min/1.73m²52.6 (8.1) [n = 6938]6.6 (1.9) [n = 4689]62.2 (1.6) [n = 12780]43.0 (15.1) [n = 304]Haemoglobin, g/dlCaltion, mmol/l2.33 (0.12) [n = 445]2.23 (0.12) [n = 445]2.23 (0.12) [n = 427]Calcium, mmol/l5.5 (1.8) [n = 6938]6.6 (1.9) [n = 4689]6.2 (1.6) [n = 1281]13.50 (1.56) [n = 2025]12.78 (1.96) [n = 227]Albumin, g/l7.51 (4.70) [n = 138]7.34 (5.42) [n = 13]38.8 (4.4) [n = 271]38.6 (4.6) [n = 57]4.3 (0.45) [n = 2238]4.4 (0.56) [n = 270]Vrine (first and third quartile), nAlbumin/creatinine, mg/l15.0 (3.4 - 51.0) [n = 2928]2.00 (5.0 - 53.0) [n = 2049]6.0 (2.9 - 18.0) [n = 721]210.6 (64.3 - 480.2) [n = 15.8]Albumin vince, mg/l15.0 (3.4 - 51.0) [n = 7291]28.6 (9.5) [n = 4889]79.1 (9.9) [n = 2147]78.6 (11.3) [n = 255]Yestolic blood pressure, mm Hg78.8 (9.7) [n = 7291]78.6 (9.5) [n = 4889]79.1 (9.9) [n = 2147]78.6 (11.3) [n = 255]Medication prescribed in 2010:Rein angiotensin blockers55.9%56.4%53.7%67.4%	Demographics (SD):				
Male sex Comorbidity: Diabetes         42.0%         33.6%         47.0%           Diabetes         32.9%         36.0%         24.5%         52.6%           Hypertension         56.2%         57.8%         53.5%         52.0%           Cardiovascular disease         35.6%         36.1%         32.4%         53.6%           Laboratory (SD), n:         Creatinie, mol/l         103.9(25.9) [n = 8792]         95.6 (18.5) [n = 5710]         47.7 (9.0) [n = 2780]         43.0 (15.1) [n = 304]           eGFR, ml/min/1.73m <sup>2</sup> 52.6 (8.1) [n = 6938]         6.6 (1.9) [n = 4689]         62.0 (1.6) [n = 1998]         7.0 (2.3) [n = 271]           Haemoglobing, g/dl         31.50 (1.56) [n = 2051         12.78 (1.96) [n = 272]         233 (0.12) [n = 445]         2.32 (0.14) [n = 72]           Phosphate, mmol/l         PTH, pmol/l         10.3 (0.18) [n = 314]         11.5 (0.20) [n = 46]         7.51 (4.70) [n = 138]         7.34 (5.42) [n = 13]           Albumin g/l         7.51 (4.70) [n = 2738]         4.4 (0.56) [n = 270]         210.6 (84.3 - 480.2) [n = 721]           Pth sphate, mmol/l         15.0 (3.4 - 51.0) [n = 2928]         2.00 (5.0 - 53.0) [n = 2049]         6.0 (2.9 - 18.0) [n = 721]         210.6 (84.3 - 480.2) [n = 211]           Albumin urine, mg/l         Albumin fcreatinine ratio         2.5 (0.9 - 6.1) [n = 522]         3.2 (0.9 - 6.4	Age in years	71.4 (11.9)	73.6 (10.2)	66.7 (13.3)	72.3 (14.0)
Comorbidity:         Jabetes         32.9%         36.0%         24.5%         52.6%           Diabetes         32.9%         36.0%         24.5%         52.0%         52.0%           Cardiovascular disease         35.6%         36.1%         32.4%         53.6%         52.0%           Laboratory (SD), n:         T         T         Cardiovascular disease         35.6%         55.4 (4.9) [n = 5709]         117.4 (23.7) [n = 2779]         136.7 (61.6) [n = 304]           eGFR, ml/min/1.73m <sup>2</sup> 52.6 (8.1) [n = 8794]         55.4 (4.9) [n = 5710]         47.7 (9.0) [n = 2780]         43.0 (15.1) [n = 304]           Haemoglobin, g/dl         6.5 (1.8) [n = 6938]         6.6 (1.9) [n = 4689]         62.2 (1.6) [n = 1998]         7.0 (2.3) [n = 251]           Haemoglobin, g/dl         23.30 (0.12) [n = 465]         12.78 (1.96) [n = 227]         23.3 (0.12) [n = 445]         23.2 (0.14) [n = 72]           Phosphate, mmol/l         1.35 0 (1.56) [n = 138]         7.34 (5.42) [n = 13]         Aldeumin, g/l         7.5 (4.70) [n = 138]         7.34 (5.42) [n = 157]           Albumin urine, mg/l         Albumin urine, mg/l         15.0 (3.4 - 51.0) [n = 2928]         20.0 (5.0 - 53.0) [n = 2049]         6.0 (2.9 - 18.0) [n = 721]         210.6 (84.3 - 480.2) [n = 158]           Albumin/creatinine ratio         2.5 (9 - 6.1) [n = 7291]         3.2 (0.9 - 6.	Male sex	40.0%	42.7%	33.6%	47.0%
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Comorbidity:				
Hypertension56.2%57.8%53.5%52.0%Cardiovascular disease35.6%36.1%32.4%53.6%Laboratory (SD), n:Creatinine, µmol/l103.9(25.9) $[n = 8792]$ 95.6 (18.5) $[n = 5709]$ 117.4 (23.7) $[n = 2779]$ 136.7 (61.6) $[n = 304]$ Fasting glucose, mmol/l6.5 (1.8) $[n = 6938]$ 6.6 (1.9) $[n = 4689]$ 6.2 (1.6) $[n = 1998]$ 7.0 (2.3) $[n = 227]$ Haemoglobin, g/dlCalcium, mmol/lPhosphate, mmol/lPTH, pmol/lAlbumin urine, mg/l15.0 (3.4–51.0) $[n = 2928]$ 20.0 (5.0-53.0) $[n = 2049]$ 6.0 (2.9-18.0) $[n = 721]$ 210.6 (84.3–480.2) $[n = 158]$ Albumin urine, mg/l15.0 (3.4–51.0) $[n = 5022]$ 3.2 (0.9-6.4) $[n = 3557]$ Diastolic blood pressure, mm Hg78.8 (9.7) $[n = 7291]$ 78.6 (9.5) $[n = 4889]$ 79.1 (9.9) $[n = 2147]$ 78.6 (11.3) $[n = 255]$ Medication prescribed in 2010:Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%46.5%45.4%2.0%<	Diabetes	32.9%	36.0%	24.5%	52.6%
Cardiovascular disease35.6% $36.1\%$ $32.4\%$ $53.6\%$ Laboratory (SD), n: Creatinine, µmol/l $103.9(25.9) [n = 8792]$ $95.6 (18.5) [n = 5709]$ $117.4 (23.7) [n = 2779]$ $136.7 (61.6) [n = 304]$ Fasting glucose, mmol/l $6.5 (1.8) [n = 6938]$ $6.6 (1.9) [n = 4689]$ $62. (1.6) [n = 1988]$ $7.0 (2.3) [n = 251]$ Haemoglobin, g/dl $7.0 (2.3) [n = 4689]$ $6.2 (1.6) [n = 1986]$ $7.0 (2.3) [n = 251]$ Calcium, mmol/lPhosphate, mmol/l $1.03 (0.18) [n = 441]$ $2.32 (0.14) [n = 722]$ Phosphate, mmol/l $7.51 (4.70) [n = 138]$ $7.34 (5.42) [n = 13]$ Phosphate, mmol/l $7.51 (4.70) [n = 138]$ $7.34 (5.42) [n = 13]$ Phosphate, mmol/l $7.51 (4.70) [n = 138]$ $7.34 (5.42) [n = 13]$ Phosphate, mmol/l $7.51 (4.70) [n = 2238]$ $2.0 (5.0-53.0) [n = 2049]$ $6.0 (2.9-18.0) [n = 721]$ Potassium, mmol/l $15.0 (3.4-51.0) [n = 2928]$ $2.0 (5.0-53.0) [n = 2049]$ $6.0 (2.9-18.0) [n = 721]$ $210.6 (84.3-480.2) [n = 158]$ Albumin urine, mg/l $15.0 (3.4-51.0) [n = 7292]$ $3.2 (0.9-6.4) [n = 3557]$ $0.9 (0.8-2.3) [n = 1254]$ $37.7 (14.8-58.2) [n = 211]$ Physical examination (SD), n $7.51 (4.70) [n = 7291]$ $78.6 (9.5) [n = 4889]$ $79.1 (9.9) [n = 2147]$ $78.6 (11.3) [n = 255]$ Medication prescribed in 2010: $7.8 (4.3\% 40.3\%$	Hypertension	56.2%	57.8%	53.5%	52.0%
Laboratory (SD), n: Creatinine, µmol/l 103.9(25.9) [n = 8792] 95.6 (18.5) [n = 5709] 117.4 (23.7) [n = 2779] 136.7 (61.6) [n = 304] eGFR, ml/min/1.73m <sup>2</sup> 52.6 (8.1) [n = 8794] 55.4 (4.9) [n = 5710] 47.7 (9.0) [n = 2780] 43.0 (15.1) [n = 304] Fasting glucose, mmol/l 6.5 (1.8) [n = 6938] 6.6 (1.9) [n = 4689] 62 (1.6) [n = 1998] 7.0 (2.3) [n = 227] Calcium, mmol/l 15.0 (1.50 [n = 2081] 2.38 (1.96) [n = 227] Calcium, mmol/l 15.0 (1.96) [n = 2049] 103 (0.18) [n = 341] 1.15 (0.20) [n = 461] Phosphate, mmol/l 7.1 (3.0) [n = 341] 1.15 (0.20) [n = 461] Phosphate, mmol/l 7.1 (3.0) [n = 271] 38.6 (4.6) [n = 571] PtH, pmol/l 4.3 (0.45) [n = 2238] 4.4 (0.56) [n = 270] Vrine (first and third quartile), n Albumin urine, mg/l 15.0 (3.4–51.0) [n = 2928] 20.0 (5.0-53.0) [n = 2049] 3.2 (0.9-6.4) [n = 3557] 0.9 (0.8-2.3) [n = 721] 210.6 (84.3–480.2) [n = 158] Albumin/creatinine ratio 2.5 (0.9-6.1) [n = 5022] 3.2 (0.9-6.4) [n = 3557] 0.9 (0.8-2.3) [n = 1254] 37.7 (14.8-58.2) [n = 211] Physical examination (SD), n Diastolic blood pressure, mm Hg 78.8 (9.7) [n = 7291] 78.6 (9.5) [n = 4889] 79.1 (9.9) [n = 2147] 78.6 (11.3) [n = 255] Systolic blood pressure, mm Hg 78.8 (9.7) [n = 7291] 78.6 (9.5) [n = 4889] 139.8 (17.5) [n = 2146] 145.1 (21.6) [n = 255] Medication prescribed in 2010: Renin angiotensin blockers 55.9% 56.4% 53.7% 67.4% B-blockers 46.3% 46.5% 45.4% 52.0% Diuretics 41.4% 40.3% 41.8% 49.3% Calcium antagonist 21.6% 21.4% 20.6% 33.7% 67.4% B-blockers 41.4% 40.3% 41.8% 49.3% Calcium antagonist 21.6% 21.4% 20.6% 32.9% Statins 47.0% 48.8% 42.6% 52.3% Vitamin D 3.7% 2.2% 6.1% 9.5% Erythropoletin 0.3% 0.1% 0.5% 13.3% Blood glucose lowering drugs 25.0% 27.3% 18.5% 40.1% Antithrombotics 46.6% 48.3% 42.1% 57.6% NSAIDS 21.3% 21.1% 22.3% 7.6%	Cardiovascular disease	35.6%	36.1%	32.4%	53.6%
$\begin{array}{c} \mbox{Creatinine, \mumol/l} & 103.9(25.9) [n = 8792] & 95.6 (18.5) [n = 5710] & 117.4 (23.7) [n = 2779] & 136.7 (61.6) [n = 304] \\ \mbox{eGFR, ml/min/1.73m^2} & 52.6 (8.1) [n = 8794] & 55.4 (4.9) [n = 5710] & 47.7 (9.0) [n = 2780] & 43.0 (15.1) [n = 304] \\ \mbox{Fasting glucose, mmol/l} & 6.5 (1.8) [n = 6938] & 6.6 (1.9) [n = 4689] & 5.2 (1.6) [n = 1998] & 7.0 (2.3) [n = 251] \\ \mbox{Fasting glucose, mmol/l} & 233 (0.12) [n = 445] & 2.32 (0.14) [n = 72] \\ \mbox{Phosphate, mmol/l} & 1.5.0 (3.16) [n = 1978] & 7.34 (5.42) [n = 13] \\ \mbox{Albumin, g/l} & 7.51 (4.70) [n = 138] & 7.34 (5.42) [n = 13] \\ \mbox{Albumin, g/l} & 7.51 (4.70) [n = 1238] & 4.4 (0.56) [n = 270] \\ \mbox{Vine (first and third quartile), n} & 38.8 (4.4) [n = 271] & 38.6 (4.4) [n = 277] \\ \mbox{Albumin vine, mg/l} & 15.0 (3.4-51.0) [n = 2928] & 20.0 (5.0-53.0) [n = 2049] \\ \mbox{Albumin vine, mg/l} & 15.0 (3.4-51.0) [n = 2928] & 3.2 (0.9-6.4) [n = 3557] & 9.9 (0.8-2.3) [n = 1254] & 37.7 (14.8-58.2) [n = 211] \\ \mbox{Physical examination (SD), n} & \\ \mbox{Distolic blood pressure, mm Hg} & 78.8 (9.7) [n = 7291] & 78.6 (9.5) [n = 4889] & 79.1 (9.9) [n = 2147] & 78.6 (11.3) [n = 255] \\ \mbox{Systolic blood pressure, mm Hg} & 142.7 (1.77) [n = 7290] & 143.8 (17.4) [n = 4889] & 19.8 (17.5) [n = 2146] & 145.1 (21.6) [n = 255] \\ \mbox{Medication prescribed in 2010:} & \\ \mbox{Revinantion SDD, n} & \\ \mbox{Diatoric blood pressure, mm Hg} & 142.7 (1.77) [n = 7290] & 78.6 (9.5) [n = 4889] & 79.1 (9.9) [n = 2147] & 78.6 (11.3) [n = 255] \\ \mbox{Medication prescribed in 2010:} & \\ \mbox{Revinantion blockers} & 55.9\% & 56.4\% & 53.7\% & 67.4\% \\ \mbox{B-blockers} & 46.3\% & 46.5\% & 45.4\% & 52.0\% \\ \mbox{Diuretics} & 41.4\% & 40.8\% & 41.8\% & 49.3\% \\ \mbox{Calcium antagonist} & 21.6\% & 21.4\% & 20.6\% & 32.9\% \\ \mbox{Statins} & 47.0\% & 48.8\% & 42.6\% & 52.3\% \\ \mbox{Vitamin D} & 3.7\% & 2.2\% & 6.1\% & 9.5\% \\ \mbox{Blood glucose lowering drugs} & 25.0\% & 27.3\% & 18.5\% & 40.1\% \\ \mbox{Stalics} & 46.6\% & 48.3\% & 42.1\% & 57.6\% \\ \mbox{Stalics} & 11.3\% & 21.3\% & 21.1\% &$	Laboratory (SD), n:				
eGFR, ml/min/1.73m <sup>2</sup> 52.6 (8.1) [n = 8794]55.4 (4.9) [n = 5710]47.7 (9.0) [n = 2780]43.0 (15.1) [n = 304]Fasting glucose, mmol/l6.5 (1.8) [n = 6938]6.6 (1.9) [n = 4689]6.2 (1.6) [n = 1998]7.0 (2.3) [n = 251]Haemoglobin, g/dl13.50 (1.56) [n = 2085]12.78 (1.96) [n = 272]2.33 (0.12) [n = 445]2.32 (0.14) [n = 72]Phosphate, mmol/l1.03 (0.18) [n = 341]1.15 (0.20) [n = 46]1.35 (0.20) [n = 46]PTH, pmol/l38.8 (4.4) [n = 271]38.6 (4.6) [n = 270]Albumin, g/l38.8 (4.4) [n = 271]38.6 (4.6) [n = 77]Potassium, mmol/l15.0 (3.4-51.0) [n = 2928]20.0 (5.0-53.0) [n = 2049]6.0 (2.9-18.0) [n = 721]Potassium, mmol/l2.5 (0.9-6.1) [n = 5022]3.2 (0.9-6.4) [n = 3557]0.9 (0.8-2.3) [n = 1254]37.7 (14.8-58.2) [n = 211]Physical examination (SD), nDiasolic blood pressure, mm Hg78.8 (9.7) [n = 7290]78.6 (9.5) [n = 4889]79.1 (9.9) [n = 2147]78.6 (11.3) [n = 255]Medication prescribed in 2010:EEERenin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Glacum antagonist21.6%21.4%20.6%32.9%Statins40.9%41.8%49.3%41.8%Medication prescribed in 2010:EEERenin angiotensin blockers55.9%56.4%	Creatinine, µmol/l	103.9(25.9) [n = 8792]	95.6 (18.5) [n = 5709]	117.4 (23.7) [n = 2779]	136.7 (61.6) [n = 304]
Fasting glucose, mmol/l6.5 (1.8) $[n = 6938]$ 6.6 (1.9) $[n = 4689]$ 6.2 (1.6) $[n = 1998]$ 7.0 (2.3) $[n = 251]$ Haemoglobin, g/dl13.50 (1.50) $[n = 2085]$ 12.78 (1.96) $[n = 227]$ 2.33 (0.12) $[n = 445]$ 2.32 (0.14) $[n = 72]$ Phosphate, mmol/l1.03 (0.18) $[n = 341]$ 1.15 (0.20) $[n = 46]$ 7.51 (4.70) $[n = 138]$ 7.34 (5.42) $[n = 13]$ PTH, pmol/l38.8 (4.4) $[n = 271]$ 38.6 (4.6) $[n = 57]$ 38.8 (4.4) $[n = 271]$ 38.6 (4.6) $[n = 57]$ Potassium, mmol/l4.3 (0.45) $[n = 2238]$ 4.4 (0.56) $[n = 270]$ 4.4 (0.56) $[n = 270]$ Urine (first and third quartile), n Albumin urine, mg/l15.0 (3.4-51.0) $[n = 2928]$ 20.0 (5.0-53.0) $[n = 2049]$ 6.0 (2.9-18.0) $[n = 721]$ 210.6 (84.3-480.2) $[n = 158]$ Albumin/creatinine ratio2.5 (0.9-6.1) $[n = 5022]$ 3.2 (0.9-6.4) $[n = 3557]$ 0.9 (0.8-2.3) $[n = 1254]$ 37.7 (14.8-58.2) $[n = 211]$ Physical examination (SD), n Diastolic blood pressure, mm Hg78.8 (9.7) $[n = 7291]$ 78.6 (9.5) $[n = 4889]$ 79.1 (9.9) $[n = 2147]$ 78.6 (11.3) $[n = 255]$ Medication prescribed in 2010: Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%46.5%45.4%52.0%Diuretics41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%52.3%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Blood glucose lowering drugs25.0%27.3%18.5%40.1% </td <td>eGFR, ml/min/1.73m<sup>2</sup></td> <td>52.6 (8.1) [n = 8794]</td> <td>55.4 (4.9) [n = 5710]</td> <td>47.7 (9.0) [n = 2780]</td> <td>43.0 (15.1) [n = 304]</td>	eGFR, ml/min/1.73m <sup>2</sup>	52.6 (8.1) [n = 8794]	55.4 (4.9) [n = 5710]	47.7 (9.0) [n = 2780]	43.0 (15.1) [n = 304]
Haemoglobin, g/dl13.50 (1.56) [n = 2085]12.78 (1.96) [n = 227]Calcium, mmol/l2.33 (0.12) [n = 445]2.32 (0.14) [n = 72]Phosphate, mmol/l1.03 (0.18) [n = 341]1.15 (0.20) [n = 46]PTH, pmol/l7.51 (4.70) [n = 138]7.34 (5.42) [n = 13]Albumin, g/l8.8 (4.4) [n = 271]38.6 (4.6) [n = 270]Potassium, mmol/l4.3 (0.45) [n = 2238]4.4 (0.56) [n = 270]Urine (first and third quartile), nAlbumin, rereating ratio2.5 (0.9-6.1) [n = 5022]3.2 (0.9-6.4) [n = 3557]Albumin/creatinine ratio2.5 (0.9-6.1) [n = 5022]3.2 (0.9-6.4) [n = 3557]0.9 (0.8-2.3) [n = 1254]37.7 (14.8-58.2) [n = 211]Physical examination (SD), nDiastolic blood pressure, mm Hg78.8 (9.7) [n = 7291]78.6 (9.5) [n = 4889]79.1 (9.9) [n = 2147]78.6 (11.3) [n = 255]Systolic blood pressure, mm Hg78.8 (9.7) [n = 7290]143.8 (17.4) [n = 4889]13.9.8 (17.5) [n = 2146]145.1 (21.6) [n = 255]Medication prescribed in 2010:Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoletin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAID <td>Fasting glucose, mmol/l</td> <td>6.5 (1.8) [n = 6938]</td> <td>6.6 (1.9) [n = 4689]</td> <td>6.2 (1.6) [n = 1998]</td> <td>7.0 (2.3) [n = 251]</td>	Fasting glucose, mmol/l	6.5 (1.8) [n = 6938]	6.6 (1.9) [n = 4689]	6.2 (1.6) [n = 1998]	7.0 (2.3) [n = 251]
Calcium, mmol/l2.33 (0.12) $[n = 445]$ 2.32 (0.14) $[n = 72]$ Phosphate, mmol/l1.03 (0.18) $[n = 341]$ 1.15 (0.20) $[n = 46]$ PTH, pmol/l7.51 (4.70) $[n = 138]$ 7.34 (5.24) $[n = 13]$ Albumin, g/l38.8 (4.4) $[n = 271]$ 38.6(4.6) $[n = 57]$ Potassium, mmol/l4.3 (0.45) $[n = 2238]$ 4.4 (0.56) $[n = 270]$ Urine (first and third quartile), nAlbumin urine, mg/l15.0 (3.4–51.0) $[n = 2928]$ 20.0 (5.0-53.0) $[n = 2049]$ 6.0 (2.9-18.0) $[n = 721]$ 210.6 (84.3–480.2) $[n = 158]$ Albumin/creatinine ratio2.5 (0.9-6.1) $[n = 5022]$ 3.2 (0.9-6.4) $[n = 3557]$ 0.9 (0.8-2.3) $[n = 1254]$ 37.7 (14.8-58.2) $[n = 211]$ Physical examination (SD), nDiastolic blood pressure, mm Hg78.8 (9.7) $[n = 7291]$ 78.6 (9.5) $[n = 4889]$ 79.1 (9.9) $[n = 2147]$ 78.6 (11.3) $[n = 255]$ Systolic blood pressure, mm Hg142.7 (17.7) $[n = 7290]$ 143.8 (17.4) $[n = 4889]$ 139.8 (17.5) $[n = 2146]$ 145.1 (21.6) $[n = 255]$ Medication prescribed in 2010:Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%46.5%41.8%49.3%Calcium antagonist21.6%21.4%20.6%52.9%Statins47.0%48.8%42.6%52.9%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6% <td>Haemoglobin, g/dl</td> <td></td> <td></td> <td>13.50 (1.56) [n = 2085]</td> <td>12.78 (1.96) [n = 227]</td>	Haemoglobin, g/dl			13.50 (1.56) [n = 2085]	12.78 (1.96) [n = 227]
Phosphate, mmol/l1.03 (0.18) $[n = 341]$ 1.15 (0.20) $[n = 46]$ PTH, pmol/l7.51 (4.70) $[n = 138]$ 7.34 (5.42) $[n = 13]$ Albumin, g/l8.8 (4.4) $[n = 271]$ 3.8 (64.6) $[n = 57]$ Potassium, mmol/l4.3 (0.45) $[n = 2238]$ 4.4 (0.56) $[n = 270]$ Urine (first and third quartile), n4.3 (0.45) $[n = 2328]$ 4.4 (0.56) $[n = 270]$ Albumin/creatinine ratio2.5 (0.9-6.1) $[n = 5022]$ 3.2 (0.9-6.4) $[n = 3557]$ 0.9 (0.8-2.3) $[n = 1254]$ 37.7 (14.8-58.2) $[n = 211]$ Physical examination (SD), nDiastolic blood pressure, mm Hg78.8 (9.7) $[n = 7291]$ 78.6 (9.5) $[n = 4889]$ 79.1 (9.9) $[n = 2147]$ 78.6 (11.3) $[n = 255]$ Systolic blood pressure, mm Hg142.7 (17.7) $[n = 7290]$ 143.8 (17.4) $[n = 4889]$ 139.8 (17.5) $[n = 2146]$ 145.1 (21.6) $[n = 255]$ Medication prescribed in 2010:Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Anithromobotics46.6%48.3%42.1%57.6%NSAIDS21.3%21.1%22.3%17.8%	Calcium, mmol/l			2.33 (0.12) [n = 445]	2.32 (0.14) [n = 72]
PTH, pmol/l7.51 (4.70) $[n = 138]$ 7.34 (5.42) $[n = 13]$ Albumin, g/l38.8 (4.4) $[n = 271]$ 38.6(4.6) $[n = 57]$ Potassium, mmol/l38.8 (4.4) $[n = 271]$ 38.6(4.6) $[n = 270]$ Urine (first and third quartile), n Albumin/creatinine ratio15.0 (3.4–51.0) $[n = 2928]$ 20.0 (5.0–53.0) $[n = 2049]$ 6.0 (2.9–18.0) $[n = 721]$ 210.6 (84.3–480.2) $[n = 158]$ Albumin/creatinine ratio2.5 (0.9–6.1) $[n = 5022]$ 3.2 (0.9–6.4) $[n = 3557]$ 0.9 (0.8–2.3) $[n = 1254]$ 37.7 (14.8–58.2) $[n = 211]$ Physical examination (SD), n Diastolic blood pressure, mm Hg78.8 (9.7) $[n = 7291]$ 78.6 (9.5) $[n = 4889]$ 79.1 (9.9) $[n = 2147]$ 78.6 (11.3) $[n = 255]$ Systolic blood pressure, mm Hg78.8 (9.7) $[n = 7290]$ 143.8 (17.4) $[n = 4889]$ 139.8 (17.5) $[n = 2146]$ 145.1 (21.6) $[n = 255]$ Medication prescribed in 2010: Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Albumin D3.7%2.2%57.6%57.6%NSAIDS21.3%21.1%22.3%77.8%	Phosphate, mmol/l			1.03 (0.18) $[n = 341]$	1.15 (0.20) [n = 46]
Albumin, g/l $38.8 (4.4) [n = 271]$ $38.6(4.6) [n = 57]$ Potassium, mmol/l $4.3 (0.45) [n = 2238]$ $4.4 (0.56) [n = 270]$ Urine (first and third quartile), nAlbumin urine, mg/l $15.0 (3.4-51.0) [n = 2928]$ $20.0 (5.0-53.0) [n = 2049]$ $6.0 (2.9-18.0) [n = 721]$ $210.6 (84.3-480.2) [n = 158]$ Albumin/creatinine ratio $2.5 (0.9-6.1) [n = 5022]$ $3.2 (0.9-6.4) [n = 3557]$ $0.9 (0.8-2.3) [n = 1254]$ $37.7 (14.8-58.2) [n = 211]$ Physical examination (SD), nDiastolic blood pressure, mm Hg $78.8 (9.7) [n = 7291]$ $78.6 (9.5) [n = 4889]$ $79.1 (9.9) [n = 2147]$ $78.6 (11.3) [n = 255]$ Systolic blood pressure, mm Hg $142.7 (17.7) [n = 7290]$ $143.8 (17.4) [n = 4889]$ $139.8 (17.5) [n = 2146]$ $145.1 (21.6) [n = 255]$ Medication prescribed in 2010:Renin angiotensin blockers $55.9\%$ $56.4\%$ $53.7\%$ $67.4\%$ B-blockers $46.3\%$ $46.5\%$ $45.4\%$ $92.0\%$ Diuretics $41.4\%$ $40.8\%$ $41.8\%$ $93.3\%$ Calcium antagonist $21.6\%$ $21.6\%$ $22.3\%$ $13\%$ Vitamin D $3.7\%$ $2.2\%$ $6.1\%$ $9.5\%$ Erythropoietin $0.3\%$ $0.1\%$ $0.5\%$ $1.3\%$ Blood glucose lowering drugs $25.0\%$ $27.3\%$ $18.5\%$ $40.1\%$ Albumin D $1.3\%$ $21.3\%$ $21.1\%$ $22.3\%$ $7.8\%$	PTH, pmol/l			7.51 (4.70) [n = 138]	7.34 (5.42) [n = 13]
Potassium, mmol/l4.3 (0.45) $[n = 2238]$ 4.4 (0.56) $[n = 270]$ Urine (first and third quartile), n Albumin urine, mg/l15.0 (3.4–51.0) $[n = 2928]$ 2.5 (0.9-6.1) $[n = 5022]$ 20.0 (5.0-53.0) $[n = 2049]$ 3.2 (0.9-6.4) $[n = 3557]$ 6.0 (2.9-18.0) $[n = 721]$ 0.9 (0.8-2.3) $[n = 1254]$ 210.6 (84.3–480.2) $[n = 158]$ 37.7 (14.8-58.2) $[n = 211]$ Physical examination (SD), n Diastolic blood pressure, mm Hg Systolic blood pressure, mm Hg78.8 (9.7) $[n = 7291]$ 142.7 (17.7) $[n = 7290]$ 78.6 (9.5) $[n = 4889]$ 142.7 (17.7) $[n = 7290]$ 79.1 (9.9) $[n = 2147]$ 139.8 (17.5) $[n = 2146]$ 78.6 (11.3) $[n = 255]$ Medication prescribed in 2010: Renin angiotensin blockers55.9% 46.3%56.4% 45.5%53.7% 45.4%67.4% 49.3%B-blockers Calcium antagonist Statins21.6% 41.4%21.4% 40.8%20.6% 42.6%32.9% 52.3%Vitamin D Erythropoietin3.7% 0.1%2.2% 6.1%51.5% 9.5%53.5% 6.1% 1.3%Blood glucose lowering drugs Antithrombotics25.0% 46.6% 48.3%21.6% 42.1%21.6% 57.6%Kithopotics Antithrombotics21.3% 46.6% 41.3%21.1% 42.3%21.6% 57.6%	Albumin, g/l			38.8 (4.4) [n = 271]	38.6(4.6) [n = 57]
Urine (first and third quartile), n Albumin urine, mg/l Albumin/creatinine ratio15.0 $(3.4-51.0)$ $[n = 2928]2.5 (0.9-6.1) [n = 5022]20.0 (5.0-53.0) [n = 2049]3.2 (0.9-6.4) [n = 721]0.9 (0.8-2.3) [n = 1254]210.6 (84.3-480.2) [n = 158]37.7 (14.8-58.2) [n = 211]Physical examination (SD), nDiastolic blood pressure, mm HgSystolic blood pressure, mm Hg78.8 (9.7) [n = 7291]142.7 (17.7) [n = 7290]78.6 (9.5) [n = 4889]143.8 (17.4) [n = 4889]79.1 (9.9) [n = 2147]139.8 (17.5) [n = 2146]78.6 (11.3) [n = 255]Medication prescribed in 2010:Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%46.5%45.4%52.0%Diuretics41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAIDs21.3%21.1%22.3%17.8%$	Potassium, mmol/l			4.3 (0.45) [n = 2238]	4.4 (0.56) [n = 270]
Albumin urine, mg/l Albumin/creatinine ratio15.0 $(3.4-51.0)$ $[n = 2928]2.5 (0.9-6.1) [n = 5022]20.0 (5.0-53.0) [n = 2049]3.2 (0.9-6.4) [n = 3557]6.0 (2.9-18.0) [n = 721]0.9 (0.8-2.3) [n = 1254]210.6 (84.3-480.2) [n = 158]37.7 (14.8-58.2) [n = 211]Physical examination (SD), nDiastolic blood pressure, mm HgSystolic blood pressure, mm Hg78.8 (9.7) [n = 7291]142.7 (17.7) [n = 7290]78.6 (9.5) [n = 4889]143.8 (17.4) [n = 4889]79.1 (9.9) [n = 2147]139.8 (17.5) [n = 2146]78.6 (11.3) [n = 255]Medication prescribed in 2010:Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%46.5%45.4%52.0%Diuretics41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%52.3%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAIDs21.3%21.3%21.3%17.8%$	Urine (first and third quartile), n				
Albumin/creatinine ratio2.5 (0.9-6.1) [n = 5022]3.2 (0.9-6.4) [n = 3557]0.9 (0.8-2.3) [n = 1254]37.7 (14.8-58.2) [n = 211]Physical examination (SD), n Diastolic blood pressure, mm Hg78.8 (9.7) [n = 7291]78.6 (9.5) [n = 4889]79.1 (9.9) [n = 2147]78.6 (11.3) [n = 255]Medication prescribed in 2010: Renin angiotensin blockers75.9%56.4%53.7%67.4%B-blockers46.3%46.5%45.4%52.0%Diuretics41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAIDs21.3%21.1%22.3%17.8%	Albumin urine, mg/l	15.0 (3.4–51.0) [n = 2928]	20.0 (5.0-53.0) [n = 2049]	6.0 (2.9-18.0) [n = 721]	210.6 (84.3–480.2) [n = 158]
Physical examination (SD), n Diastolic blood pressure, mm Hg78.8 (9.7) [n = 7291] 142.7 (17.7) [n = 7290]78.6 (9.5) [n = 4889] 143.8 (17.4) [n = 4889]79.1 (9.9) [n = 2147] 139.8 (17.5) [n = 2146]78.6 (11.3) [n = 255]Medication prescribed in 2010: Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%46.5%45.4%52.0%Diuretics41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAIDS21.3%21.1%22.3%17.8%	Albumin/creatinine ratio	2.5 (0.9-6.1) [n = 5022]	3.2 (0.9-6.4) [n = 3557]	0.9 (0.8-2.3) [n = 1254]	37.7 (14.8-58.2) [n = 211]
Physical examination (SD), n       Diastolic blood pressure, mm Hg       78.8 (9.7) [n = 7291]       78.6 (9.5) [n = 4889]       79.1 (9.9) [n = 2147]       78.6 (11.3) [n = 255]         Systolic blood pressure, mm Hg       142.7 (17.7) [n = 7290]       143.8 (17.4) [n = 4889]       139.8 (17.5) [n = 2146]       145.1 (21.6) [n = 255]         Medication prescribed in 2010:       Renin angiotensin blockers       55.9%       56.4%       53.7%       67.4%         B-blockers       46.3%       46.5%       45.4%       52.0%         Diuretics       41.4%       40.8%       41.8%       49.3%         Calcium antagonist       21.6%       21.4%       20.6%       32.9%         Statins       47.0%       48.8%       42.6%       52.3%         Vitamin D       3.7%       2.2%       6.1%       9.5%         Erythropoietin       0.3%       0.1%       0.5%       1.3%         Blood glucose lowering drugs       25.0%       27.3%       18.5%       40.1%         Antithrombotics       46.6%       48.3%       42.1%       57.6%         NSAIDs       21.3%       21.1%       22.3%       17.8%					
Diastolic blood pressure, mm Hg $78.8 (9.7) [n = 7291]$ $78.6 (9.5) [n = 4889]$ $79.1 (9.9) [n = 2147]$ $78.6 (11.3) [n = 255]$ Systolic blood pressure, mm Hg $142.7 (17.7) [n = 7290]$ $143.8 (17.4) [n = 4889]$ $139.8 (17.5) [n = 2146]$ $145.1 (21.6) [n = 255]$ Medication prescribed in 2010: Renin angiotensin blockers $55.9\%$ $56.4\%$ $53.7\%$ $67.4\%$ B-blockers $46.3\%$ $46.5\%$ $45.4\%$ $52.0\%$ Diuretics $41.4\%$ $40.8\%$ $41.8\%$ $49.3\%$ Calcium antagonist $21.6\%$ $21.4\%$ $20.6\%$ $32.9\%$ Statins $47.0\%$ $48.8\%$ $42.6\%$ $52.3\%$ Vitamin D $3.7\%$ $2.2\%$ $6.1\%$ $9.5\%$ Erythropoietin $0.3\%$ $0.1\%$ $0.5\%$ $1.3\%$ Blood glucose lowering drugs $25.0\%$ $27.3\%$ $18.5\%$ $40.1\%$ Antithrombotics $46.6\%$ $48.3\%$ $42.1\%$ $57.6\%$ NSAIDs $21.3\%$ $21.1\%$ $22.3\%$ $17.8\%$	Physical examination (SD), n				
Systolic blood pressure, mm Hg $142.7 (17.7) [n = 7290]$ $143.8 (17.4) [n = 4889]$ $139.8 (17.5) [n = 2146]$ $145.1 (21.6) [n = 255]$ Medication prescribed in 2010: Renin angiotensin blockers $55.9\%$ $56.4\%$ $53.7\%$ $67.4\%$ B-blockers $46.3\%$ $46.5\%$ $45.4\%$ $52.0\%$ Diuretics $41.4\%$ $40.8\%$ $41.8\%$ $49.3\%$ Calcium antagonist $21.6\%$ $21.4\%$ $20.6\%$ $32.9\%$ Statins $47.0\%$ $48.8\%$ $42.6\%$ $52.3\%$ Vitamin D $3.7\%$ $2.2\%$ $6.1\%$ $9.5\%$ Erythropoietin $0.3\%$ $0.1\%$ $0.5\%$ $1.3\%$ Blood glucose lowering drugs $25.0\%$ $27.3\%$ $18.5\%$ $40.1\%$ Antithrombotics $46.6\%$ $48.3\%$ $42.1\%$ $57.6\%$ NSAIDs $21.3\%$ $21.1\%$ $22.3\%$ $17.8\%$	Diastolic blood pressure, mm Hg	/8.8 (9./) [n = /291]	78.6 (9.5) [n = 4889]	/9.1 (9.9) [n = 214/]	78.6(11.3) [n = 255]
Medication prescribed in 2010:         55.9%         56.4%         53.7%         67.4%           B-blockers         46.3%         46.5%         45.4%         52.0%           Diuretics         41.4%         40.8%         41.8%         49.3%           Calcium antagonist         21.6%         21.4%         20.6%         32.9%           Statins         47.0%         48.8%         42.6%         52.3%           Vitamin D         3.7%         2.2%         6.1%         9.5%           Erythropoietin         0.3%         0.1%         0.5%         1.3%           Blood glucose lowering drugs         25.0%         27.3%         18.5%         40.1%           Antithrombotics         46.6%         48.3%         42.1%         57.6%           NSAIDs         21.3%         21.1%         22.3%         17.8%	Systolic blood pressure, mm Hg	142.7 (17.7) [n = 7290]	143.8 (17.4) [n = 4889]	139.8 (17.5) [n = 2146]	145.1 (21.6) [n = 255]
Renin angiotensin blockers55.9%56.4%53.7%67.4%B-blockers46.3%46.5%45.4%52.0%Diuretics41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAIDs21.3%21.1%22.3%17.8%	Medication prescribed in 2010:				
B-blockers46.3%46.5%45.4%52.0%Diuretics41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAIDs21.3%21.1%22.3%17.8%	Renin angiotensin blockers	55.9%	56.4%	53.7%	67.4%
Diuretics41.4%40.8%41.8%49.3%Calcium antagonist21.6%21.4%20.6%32.9%Statins47.0%48.8%42.6%52.3%Vitamin D3.7%2.2%6.1%9.5%Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAIDs21.3%21.1%22.3%17.8%	B-blockers	46.3%	46.5%	45.4%	52.0%
Calcium antagonist         21.6%         21.4%         20.6%         32.9%           Statins         47.0%         48.8%         42.6%         52.3%           Vitamin D         3.7%         2.2%         6.1%         9.5%           Erythropoietin         0.3%         0.1%         0.5%         1.3%           Blood glucose lowering drugs         25.0%         27.3%         18.5%         40.1%           Antithrombotics         46.6%         48.3%         42.1%         57.6%           NSAIDs         21.3%         21.1%         22.3%         17.8%	Diuretics	41.4%	40.8%	41.8%	49.3%
Statins         47.0%         48.8%         42.6%         52.3%           Vitamin D         3.7%         2.2%         6.1%         9.5%           Erythropoietin         0.3%         0.1%         0.5%         1.3%           Blood glucose lowering drugs         25.0%         27.3%         18.5%         40.1%           Antithrombotics         46.6%         48.3%         42.1%         57.6%           NSAIDs         21.3%         21.1%         22.3%         17.8%	Calcium antagonist	21.6%	21.4%	20.6%	32.9%
Vitamin D         3.7%         2.2%         6.1%         9.5%           Erythropoietin         0.3%         0.1%         0.5%         1.3%           Blood glucose lowering drugs         25.0%         27.3%         18.5%         40.1%           Antithrombotics         46.6%         48.3%         42.1%         57.6%           NSAIDs         21.3%         21.1%         22.3%         17.8%	Statins	47.0%	48.8%	42.6%	52.3%
Erythropoietin0.3%0.1%0.5%1.3%Blood glucose lowering drugs25.0%27.3%18.5%40.1%Antithrombotics46.6%48.3%42.1%57.6%NSAIDs21.3%21.1%22.3%17.8%	Vitamin D	3.7%	2.2%	6.1%	9.5%
Blood glucose lowering drugs         25.0%         27.3%         18.5%         40.1%           Antithrombotics         46.6%         48.3%         42.1%         57.6%           NSAIDs         21.3%         21.1%         22.3%         17.8%	Erythropoietin	0.3%	0.1%	0.5%	1.3%
Antithrombotics         46.6%         48.3%         42.1%         57.6%           NSAIDs         21.3%         21.1%         22.3%         17.8%	Blood glucose lowering drugs	25.0%	27.3%	18.5%	40.1%
NSAIDs 21.3% 21.1% 22.3% 17.8%	Antithrombotics	46.6%	48.3%	42.1%	57.6%
	NSAIDs	21.3%	21.1%	22.3%	17.8%

"Primary care group": treatment in primary care. "Consultation group": consultation of a nephrologist without referral. "Referral group": referral to secondary care.

rural based on the Statistics Netherlands' Key figures postcode areas database of 2004), and General Practice Information System (Web appendix Table 2).

#### Data analysis

CKD stage prevalence was calculated using the registered population aged 18 years and over as denominator. We used descriptive statistics to assess adherence to process and outcome indicators and to evaluate GPs' recognition of CKD. The guideline advises annual monitoring, but in routine general practice the monitoring could take place outside this 12-month timeframe. We took this into account and extended the period to 15 months prior to data extraction on 1 March 2011. Because of the hierarchical structure of our data (patients nested within practices) the analyses were based on the multilevel logistic regression model (PROC GLIMMIX in SAS). To identify patient and practice characteristics associated with high-quality care, we performed a model with a random intercept and all other variables were fixed. The type of General Practice Information System was considered a confounder, since it could affect the quality of data recording. We started with a full model including all independent variables and excluded statistically non-significant variables one by one in a backward procedure. We considered a *p*-value < 0.05 as statistically significant. Descriptive analysis was conducted using SPSS version 20.0<sup>TM</sup> (IBM PASW statistics 20, IBM, Armonk, NY, USA) and multilevel logistic regression analysis was conducted using SAS V9.2<sup>TM</sup> (SAS Institute, Cary, NC, USA).

# Results

### **Practice population**

The 47 practices served a population of 207 469 people of whom 162 562 were aged 18 or older. Data on renal function (n = 59 728) or albuminuria (n = 19 217) were present for 59 728 adult patients (31%). More data were

Table 4a. Significant results of multilevel logistic regression model on the association between patient and practicecharacteristics and QoC.

Variable		Μ	onitoring disease progress	sion	
	eGFR	Albumin urine	Fasting glucose	Blood pressure	Complete
Patient characteristics:					
Age (18-45 years as refere	nce)				
45-60 years	1.46 (1.04-2.05)	0.99 (0.71-1.40)	1.61 (1.16–2.25)	1.82 (1.29–2.58)	1.15 (0.79–1.68)
60–75 years	1.99 (1.43-2.76)	1.03 (0.74-1.24)	2.09 (1.52-2.87)	2.59 (1.85-3.61)	1.43 (0.99-2.05)
>75 years	2.47 (1.77-3.43)	0.81 (0.58-1.12)	1.58 (1.15-2.18)	2.90 (2.08-4.04)	1.20 (0.83-1.72)
Male sex		1.28 (1.16-1.42)			1.26 (1.13-1.40)
Diabetes	2.98 (2.58-3.45)	9.33 (8.34-10.44)	7.07 (6.22-8.04)	4.14 (3.62-4.74)	10.97 (9.75-12.34)
Hypertension	1.84 (1.64-2.07)	2.15 (1.94–2.38)	2.42 (2.19-2.68)	4.00 (3.58-4.48)	2.45 (2.19-2.73)
Cardiovascular disease	0.87 (0.76-0.98)	0.77 (0.69–0.86)	0.82 (0.73-0.91)		0.76 (0.68–0.86)
Practice characteristics:					
Urban location		0.57 (0.37–0.88)		0.52 (0.29–0.93)	

Results are shown as odds ratios with 95% confidence intervals in parentheses. Outcomes on practice type and vocational training practice were not significant.

available for the elderly: 71% of the population over 65 years had a renal function assessment. Diabetes was recorded in 10 623 patients (6.5% of the population), hypertension in 23 647 (14.5%), and cardiovascular disease in 12 938 (8.0%).

## Study population

A total of 9288 patients met the criteria for CKD, resulting in a known adult prevalence of CKD in our study of 5.7%. K\DOQI stages 1–2 accounted for 1.06% (n = 1719) and stages 3–5 for 4.66% (n = 7569). Of these, 494 patients received secondary renal care and were excluded from analysis. In the cohort of 8794 patients treated by their GP, the guideline recommended treatment in primary care in 64.9%, consultation with a nephrologist in 31.6%, and referral in 3.5% of patients. Table 3 provides detailed characteristics.

## **Process and outcome indicators**

GPs completely followed the guideline in 42% (95% CI 41–43%) of their CKD patients for monitoring disease progression and in 2.4% (95% CI 1.9–2.9%) for monitoring metabolic parameters. Blood pressure was below 140/90 mmHg in 43.1% (95% CI 41.8–44.3%) and below 130/80 mmHg in 16.4% (95% CI 15.5–17.3%) of patients in whom a blood pressure measurement was available (n = 6325). All patients considered, the achievement of blood pressure targets amounted to 31.0% and 11.8% respectively. GPs recognized decreased eGFR in 31.4% (95% CI 30–32%) by using ICPC code U99.1 for impaired renal function. Table 2 provides further details on quality indicators.

#### Associated patient and practice characteristics

A history of diabetes (OR 10.97; 95% CI 9.75–12.34) or hypertension (OR 2.45; 95% CI 2.19–2.73), and male

gender were associated with better monitoring of disease progression (Table 4a). A history of cardiovascular disease was negatively correlated with monitoring of disease progression. Cardiovascular disease and highest age were positively associated with monitoring of metabolic parameters (Table 4b). Factors associated with recognition of CKD were a history of cardiovascular disease, hypertension, female sex, and highest age. Blood pressure outcome target < 140/90 mmHg was positively associated with a history of cardiovascular disease, and had a negative correlation with highest age.

# Discussion

# Summary

Our results show room for improvement in all aspects of CKD management, yet most clinical relevance lies in the achievement of blood pressure targets (43% < 140/90mmHg). A history of diabetes was strongly associated with high QoC.

# Prevalence and recognition

In the Netherlands, the estimated community prevalence of CKD is 10.4%, with 5.1% in CKD stages 1–2, and 5.3% in stages 3–5.[11] For our data, this implies that respectively 21% and 88% of expected CKD patients could have been ascertained in primary care with the available laboratory results. However, recognized decreased eGFR was lower at only 31.4% of potentially identifiable patients. Recognition is important, as it is associated with better quality of care.[12]

#### Strengths and limitations

A key strength of our study is the utilization of routine general practice data, which provides a realistic view on quality of care. Our study represents a large proportion

VariableHaemoglobinCalciumPhosphatePTHSerum albuminPotassiumCompleteRecognition $< 140^{1}$ Patient characteristics:Patient characteristics:Age (18-45 years as reference)Age (18-45 years as reference)Age (18-45 years as reference) $47-60$ years $100$ ( $0.66-1.53$ ) $3.10$ ( $0.74-1301$ ) $447$ ( $0.60-33.16$ ) $5.63$ ( $1.37-5.768$ ) $2.75$ ( $1.69-4.40$ ) $5.63$ ( $1.36-23.29$ ) $9.52$ ( $1.30-69.60$ ) $5.75$ years $2.26$ ( $1.47-3.49$ ) $10.22$ ( $2.48-4.214$ ) $10.22$ ( $2.48-4.214$ ) $10.22$ ( $2.48-4.214$ ) $10.22$ ( $2.48-4.214$ ) $10.22$ ( $2.69-1.60$ ) $5.68$ ( $1.37-23.55$ ) $4.19$ ( $2.57-6.82$ ) $0.73$ ( $0.52-0.93$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.52-0.94$ ) $0.73$ ( $0.50-0.94$ ) $0.73$ ( $0.50-0.94$ ) $0.73$ ( $0.50-0.94$ ) $0.73$ ( $0.50-0.94$ ) $0.73$ ( $0.50-0.94$ ) $0.73$ ( $0.50-0.95$ ) $0.73$ ( $0.50-0.94$				Monitoring met	abolic parameters:				Outcome	variables
Patient characteristics:Patient characteristics:Ist (0.37-6.78) $2.16$ (1.34-347) $1.53$ (0.91-2.55) $1.11$ (1Age (18-45 years as reference) $3.10$ (0.56-1.53) $3.10$ (0.74-1301) $4.47$ (0.60-33.16) $1.57$ (0.37-6.78) $2.16$ (1.34-347) $1.53$ (0.91-2.55) $1.11$ (1 $45-60$ years $1.05$ (0.66-1.53) $3.10$ (0.74-1301) $4.47$ (0.60-33.16) $3.03$ (0.73-12.69) $2.73$ (1.69-4.40) $2.22$ (1.47-349) $2.22$ (1.47-349) $0.22$ (1.47-349) $0.22$ (1.47-349) $0.27$ (0.68-0.91) $0.78$ (0.67-0.91) $0.27$ (0.62-0.91) $0.27$ (0.55-0.97) $1.9$ (1.37-23.55) $4.19$ (2.57-6.82) $3.95$ (2.41-6.48) $0.59$ (0.91-2.55) $0.78$ (0.57-0.91) $0.27$ (0.52-0.97) $0.73$ (0.55-0.97) $1.92$ (1.37-23.255) $4.19$ (2.57-6.82) $0.58$ (0.78-0.97) $0.78$ (0.57-0.084) $0.73$ (0.55-0.97) $1.53$ (1.37-23.255) $4.19$ (2.57-6.82) $0.58$ (0.78-0.97) $0.78$ (0.52-0.084) $0.73$ (0.55-0.97) $1.53$ (1.37-23.255) $1.19$ (1.5-1.67) $1.42$ (1.27-1.58) $0.57$ (1 $0.72$ (0.52-0.84) $0.73$ (0.55-0.97) $1.53$ (1.5-1.67) $1.22$ (1.36-1.77) $1.37$ (1.72-1.58) $0.57$ (1Practice tharacteristics: $1.23$ (1.03-1.46) $0.73$ (0.55-0.97) $1.52$ (1.36-1.77) $1.37$ (1.27-1.58) $0.57$ (1.36-1.77) $1.37$ (1.27-1.58)Practice tharacteristics: $1.23$ (1.03-1.46) $0.73$ (0.55-0.97) $1.23$ (0.55-0.97) $1.22$ (1.36-1.77) $1.37$ (1.27-1.58)Practice tharacteristics: $0.22$ (0.50-0.92) $0.23$ (0.50-0.95) $0.23$ (0.78-0.296	Variable	Haemoglobin	Calcium	Phosphate	PTH Serum albumin	Potassium	Complete	Recognition	<140/90 mmHg	<130/80 mmHg
45-00 years1.00 (0.601.53)3.10 (0.44-13.01)4.47 (0.6033.16)1.57 (0.31-2.69)2.16 (1.34-3.47)1.53 (0.91-2.55)1.11 (1 $60-75$ years1.05 (0.69-1.60)5.63 (1.36-23.29)9.52 (1.30-69.60)3.03 (0.73-12.69)2.73 (1.69-4.40)2.72 (1.66-4.46)0.79 (0.78 $>75$ years2.26 (1.47-3.49)10.22 (2.48-42.14)15.39 (2.11-112.23)5.68 (1.37-23.55)4.19 (2.57-6.82)3.35 (2.41-6.48)0.59 (0.78Male sex0.78 (0.67-0.91)0.023 (0.55-0.97)0.73 (0.55-0.97)1.59 (1.32-1.92)1.17 (1Diabetes0.62 (0.52-0.73)0.73 (0.55-0.97)1.59 (1.37-23.27)1.1920.57 (0.78-0.97)Diabetes0.72 (0.62-0.84)0.73 (0.55-0.97)1.59 (1.37-13.53)0.57 (1Practice characteristics:1.23 (1.03-1.46)1.37 (1.51-1.67)1.59 (1.15-1.67)1.37 (1)Practice type (solo practice as reference)1.23 (1.03-1.46)1.37 (1.36-1.71)1.37 (1.36-1.71)1.37 (1)Practice type (solo practice as reference)1.23 (1.03-1.46)1.37 (1.52-1.67)1.37 (1.52-1.67)1.37 (1)Diabetes0.72 (0.52-0.84)1.23 (1.03-1.46)1.52 (1.36-1.71)1.37 (1)Practice type (solo practice as reference)1.23 (1.03-1.46)1.52 (1.36-1.71)1.37 (1.52-1.67)Practice type (solo practice as reference)1.23 (1.22-2.26)1.24 (1.27-1.58)0.57 (1.36-1.71)Practice type (solo practice as reference)1.23 (1.28-3.20)0.69 (0.50-0.95)3.30 (1.17-9.36)Practice type (solo practice1.23 (1.28-3.20)<	Patient characteristics: Age (18–45 years as referenc	.e)								
>75 years $2.26$ ( $1.47-3.49$ ) $10.22$ ( $2.48-42.14$ ) $15.39$ ( $2.11-112.23$ ) $5.68$ ( $1.37-23.55$ ) $4.19$ ( $2.57-6.82$ ) $3.95$ ( $2.41-6.48$ ) $0.59$ ( $0.7$ )Male sex $0.78$ ( $0.67-0.91$ ) $0.73$ ( $0.55-0.97$ ) $1.59$ ( $1.32-1.92$ ) $0.87$ ( $0.78-0.97$ )Diabetes $0.02$ ( $0.52-0.73$ ) $0.73$ ( $0.55-0.97$ ) $1.59$ ( $1.32-1.92$ ) $0.87$ ( $0.78-0.97$ )Hypertension $0.72$ ( $0.62-0.84$ ) $0.73$ ( $0.55-0.97$ ) $1.59$ ( $1.32-1.92$ ) $1.42$ ( $1.27-1.58$ ) $0.57$ ( $0.78-0.97$ )Hypertension $0.72$ ( $0.62-0.84$ ) $0.73$ ( $0.55-0.97$ ) $1.39$ ( $1.15-1.67$ ) $1.42$ ( $1.27-1.58$ ) $0.57$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.71$ ) $1.37$ ( $1.26-1.66$ )Practice type (solo practice as reference) $1.23$ ( $1.03-1.46$ ) $1.26$ ( $1.02-3.48$ ) $1.27$ ( $0.72-2.26$ ) $3.30$ ( $1.17-9.36$ )Practice type (solo practice $1.28-3.20$ ) $0.69$ ( $0.50-0.95$ ) $3.30$ ( $1.17-9.36$ )Vocational training practice $2.03$ ( $1.28-3.20$ ) $0.69$ ( $0.50-0.95$ ) $3.30$ ( $1.17-9.36$ )	45-60 years 60-75 years	1.00 (0.66–1.53) 1.05 (0.69–1.60)	3.10 (0./4–13.01) 5.63 (1.36–23.29)	4.47 (0.60–33.16) 9.52 (1.30–69.60)	1.57 (0.37–6.78) 3.03 (0.73–12.69)	2.73 (1.69–4.40) 2.73 (1.69–4.40)		(cc.2-10.0) cc.1 2.72 (1.66–4.46)	1.11 (0./2–1./2) 0.79 (0.52–1.20)	
Male sex $0.78 (0.56 - 0.91)$ $0.73 (0.25 - 0.97)$ $0.87 (0.78 - 0.97)$ Diabetes $0.62 (0.52 - 0.73)$ $0.62 (0.52 - 0.73)$ $0.42 (1.27 - 1.59)$ $0.57 (1.27 - 1.59)$ Hypertension $0.72 (0.62 - 0.84)$ $0.72 (0.62 - 0.84)$ $1.42 (1.27 - 1.59)$ $0.57 (1.36 - 1.71)$ Cardiovascular disease $1.23 (1.03 - 1.46)$ $1.39 (1.15 - 1.67)$ $1.42 (1.27 - 1.59)$ $0.57 (1.36 - 1.71)$ Practice characteristics:Practice type (solo practice as reference)DuoGroupContonal training practice	>75 years	2.26 (1.47–3.49)	10.22 (2.48–42.14)	15.39 (2.11–112.23)	5.68 (1.37–23.55)	4.19 (2.57–6.82)		3.95 (2.41–6.48)	0.59 (0.39–0.89)	
Matrix	Male sex	0.78 (0.67-0.91)		0.73 (0.55–0.97)		1 50 (1 32-1 02)		0.87 (0.78- 0.97)		1 18 /1 02 1 36)
Cardiovascular disease 1.23 (1.03–1.46) 1.52 (1.36–1.71) 1.37 (1 Practice characteristics: Practice type (solo practice as reference) Duo Group Vocational training practice Vocational training practice	Hypertension	0.72 (0.62-0.84)				2.78 (2.36–3.27)		1.42 (1.27–1.58)	0.57 (0.51–0.64)	0.49 (0.43–0.57)
Practice characteristics: Practice type (solo practice as reference) Duo Group Vocational training practice	Cardiovascular disease	1.23 (1.03–1.46)				1.39 (1.15–1.67)		1.52 (1.36–1.71)	1.37 (1.22–1.53)	1.69 (1.47–1.94)
Practice type (solo practice as reference) 1.88 (1.02–3.48) 1.27 (0.72–2.26) Group 2.03 (1.28–3.20) 0.69 (0.50–0.95) 3.30 (1.17–9.36)	Practice characteristics:									
Group Vocational training practice 2.03 (1.28–3.20) 0.69 (0.50–0.95) 3.30 (1.17–9.36)	Practice type (solo practice à Duo	ıs reference)				1.88 (1.02–3.48)				
Vocational training practice	Group					1.27 (0.72–2.26)				
0.70 (0.49–0.99)	Vocational training practice Urban location				2.03 (1.28–3.20)	0.69 (0.50–0.95) 0.70 (0.49–0.99)	3.30 (1.17–9.36)			

of the (potential) CKD population in primary care, as data on renal function were available for most patients over 65 years. To accurately report on QoC in routine general practice, we focused on patients under care of their GP.

Several limitations should be considered. We applied the guideline classification based on single creatinine and albuminuria assessments whereas at least two or three measurements are advised. This might have led to less accurate classification, but is in line with other CKD studies. The practices' intrinsic motivation to participate in the CONTACT trial might have led to a selection bias with possible overestimation of QoC. Conversely QoC might be underestimated due to analysis of data routinely recorded in the EMR. It is not unlikely that blood pressure was measured but not registered. Furthermore, GPs had little time to implement the guideline within our studied timeframe (1 December 2009 to 1 March 2011) considering its introduction in November 2009.

#### Comparison with existing literature

Our results on monitoring of disease progression are in line with previous studies. Research on CKD stages 3-4 conducted within multi-specialty group practices, housing both GPs and nephrologists, found a comparable eGFR assessment rate (86%), and a slightly lower albuminuria testing rate (30%).[6] Also, impressive results are shown in the United Kingdom, where they recorded an 82% albuminuria testing rate in CKD stages 3–5.[13] Of possible influence is the pay for performance system: the Quality and Outcomes Framework (QOF). In the Netherlands, GPs are not given incentives to manage CKD, but for diabetes management local financial incentives exist.[14]

Outcomes on metabolic parameter monitoring were relatively low in our study. The earlier mentioned multispecialty group study reported two- to threefold more monitoring of haemoglobin, calcium, and PTH.[6] Nephrologists' presence close to GPs may account for these differences.

The overall level of CKD recognition is not exceptional in our study, as other studies report electronic documentation of CKD of between 4% and 38%.[6,7,12,15] Low recognition may well be related to hurdles that doctors experience in assigning a CKD diagnosis.[16]

Blood pressure targets were equally met in most other studies: an Italian study reported blood pressures < 140/ 90mmHg in 45% of CKD patients; other reports mention blood pressures < 130/80mmHg in 13% to 54% of patients depending on the included CKD stages.[12,17,18] The QOF shows strong results with blood pressures < 140/85mmHg in 74% of the CKD population.[13]

Research shows that patient factors associated with high QoC are concurrent diabetes, hypertension, or coronary artery disease, age > 75 years, and male sex.[6,18–20] Our findings are comparable, except that cardiovascular disease was negatively associated with monitoring of disease progression. Possibly, monitoring was left to the discretion of a cardiologist.

Results derived from the QOF show that vocational training practices, group practices, and practices in less socially deprived areas were associated with a higher QoC in general.[21,22]

# Implications for research and/or practice

In CKD stages 1 and 2 we found a high QoC for monitoring of disease progression. We hypothesize that the high prevalence of diabetes in these patients (62%), and their treatment supported by an evidence-based primary care-generated diabetes guideline, is key to their renal function and albuminuria assessments.[23,24] This guideline has been developed in, by, and for general practice, with the objective to translate disease-specific recommendations into a framework of person-centred care over time. Since its introduction in 1989, the guideline has been revised and updated in relation to scientific progress but also following practice-based experiences in its implementation.[25] Our findings suggest that embedding of CKD care in a support model and organization comparable to diabetes would stand the best chance to improve QoC in general practice.[26] This should not be a new single disease model, but should support GP-based CKD care and preferably be integrated in existing support models for chronic care to prevent fragmentation.[27]

Feedback on laboratory results and GP education to increase CKD recognition can assist GPs to better identify CKD patients.[12] Periodic reviewing of EMRs, with or without the support of nephrologists, could be a component of support models.[28] Introduction of a pay-for-performance system for CKD management has shown favourable results in the UK.[17] Quality improvement strategies should focus on better recognition, systematic monitoring of disease progression including albuminuria, and blood pressure targets.

## Acknowledgements

The authors would like to thank the Dutch Kidney Foundation, participating practices, Lea Peters, research assistant, and Reinier Akkermans, statistician.

#### Funding

The Dutch Kidney Foundation funded the study. Amgen provided an additional non-conditional grant.

# **Ethical approval**

Ethical approval was not required according to the accredited Medical Research Ethics Committee Arnhem/Nijmegen registration number 2010/187. This study was performed according to the Code of Conduct for Health Research, which has been approved by the Data Protection Authorities for conformity with the applicable Dutch privacy legislation.

#### **Disclosure statement**

The Department of Primary and Community Care received a non-conditional grant from Amgen. Jack Wetzels received research grants from Amgen, Genzyme, and Pfizer for the Masterplan study. All other authors have no conflicting interests.

#### References

- National Kidney Foudation. K/DOQI Guidelines [internet]. New York; 2002. Available from: http://www.kidney. org/professionals/KDOQI/guidelines\_commentaries.cfm [accessed 2012].
- [2] National Collaborating Centre for Chronic Conditions Chronic Kidney Disease. National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London: Royal College of Physicians; 2008. available from http://www.nice.org.uk/nicemedia/ pdf/CG073NICEGuideline.pdf (last accessed 15 November 2012).
- [3] De Grauw WJC KH, Bilo HJG, Faber EF, et al. Landelijke transmurale afspraak chronische nierschade [Dutch guideline for primary care and nephrology]. Huisarts Wet. 2009;52:586–597.
- [4] Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351:1296–1305.
- [5] Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–2081.
- [6] Allen AS, Forman JP, Orav EJ, et al. Primary care management of chronic kidney disease. J Gen Intern Med. 2011;2:386–392.
- [7] Stevens PE, O'Donoghue DJ, de Lusignan S, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72:92–99.
- [8] Luijks HD, Loeffen MJ, Lagro-Janssen AL, et al. GPs' considerations in multimorbidity management: a qualitative study. Br J Gen Pract. 2012;62:e503–510.
- [9] Wonca International Classification Committee. ICPC-2: International Classification of Primary Care. 2nd edn. Prepared by the International Classification Committee of WONCA (WICC). Oxford, UK: Oxford University Press; 1998.
- [10] WHO Collaborating Centre for Drug Statistics Methodology. (2006) Guidelines for ATC classification and DDD assignment. Oslo: WHO; 2007.

- [11] De Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl. 2005(98):S25–29.
- [12] Ravera M, Noberasco G, Weiss U, et al. CKD awareness and blood pressure control in the primary care hypertensive population. Am J Kidney Dis. 2011;57:71–77.
- [13] Stevens PE, de Lusignan S, Farmer CK, Tomson CR. Engaging primary care in CKD initiatives: the UK experience. Nephrol Dial Transplant. 2012;27(Suppl 3): iii5–iii11.
- [14] Struijs JN, Baan CA. Integrating care through bundled payments: lessons from the Netherlands. N Engl J Med. 2011;364:990–991.
- [15] De Lusignan S, Chan T, Stevens P, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22:234–241.
- [16] The NHS Information Centre. Centre TNI. Quality and Outcomes Framework Achievement Data 2010/11. 2012. Available from: http://www.hscic.gov.uk/catalogue/ PUB04396/qof-10-11-rep.pdf (last accessed 12 November 2012).
- [17] Blakeman T, Protheroe J, Chew-Graham C, et al. Understanding the management of early-stage chronic kidney disease in primary care: a qualitative study. Br J Gen Pract. 2012;62:233–242.
- [18] Parikh NI, Hwang SJ, Larson MG, et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166:1884–1891.
- [19] Wyatt C, Konduri V, Eng J, Rohatgi R. Reporting of estimated GFR in the primary care clinic. Am J Kidney Dis. 2007;49:634–641.
- [20] De Lusignan S, Nitsch D, Belsey J, et al. Disparities in testing for renal function in UK primary care: crosssectional study. Fam Pract. 2011;28:638–646.

- [21] Akbari A, Swedko PJ, Clark HD, et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program. Arch Intern Med. 2004;164:1788–1792.
- [22] Ashworth M, Armstrong D. The relationship between general practice characteristics and quality of care: a national survey of quality indicators used in the UK Quality and Outcomes Framework, 2004–5. BMC Fam Pract. 2006;7:68.
- [23] Ashworth M, Schofield P, Seed P, et al. Identifying poorly performing general practices in England: a longitudinal study using data from the quality and outcomes framework. J Health Services Res Policy. 2011;16:21–27.
- [24] Dhoul N, de Lusignan S, Dmitrieva O, et al. Quality achievement and disease prevalence in primary care predicts regional variation in renal replacement therapy (RRT) incidence: an ecological study. Nephrol Dial Transplant. 2012;27:739–746.
- [25] Rutten GEHM De Grauw WJC, Nijpels G, Houweling ST, et al. NHG-Standaard Diabetes mellitus type 2 [The Dutch College of General Practitioners practice guideline 'Diabetes Mellitus type 2']. Huisarts Wet. 2013;56:51225.
- [26] Van Doorn-Klomberg AL, Braspenning JC, Wolters RJ, et al. Organizational determinants of high-quality routine diabetes care. Scand J Primary Health Care. 2014;32:124–131.
- [27] Van Hateren KJ, Drion I, Kleefstra N, et al. A prospective observational study of quality of diabetes care in a shared care setting: trends and age differences (ZODIAC-19). BMJ Open. 2012;2(4).
- [28] Van Weel C, Carelli F, Gerada C. Reforming primary care: innovation or destruction? Br J Gen Pract. 2012;62:43–44.
- [29] Rayner HC, Hollingworth L, Higgins R, Dodds S. Systematic kidney disease management in a population with diabetes mellitus: turning the tide of kidney failure. BMJ Qual Safety. 2011;20:903–910.